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We analyzed clinical effects and mechanism of flutamide as a second-line antiandrogen 
for combined androgen blockade (CAB) in patients with castration-resistant prostate 
cancer (CRPC) treated with bicalutamide as the first-line antiandrogen. 
Methods 
Our study population consisted of 16 patients with CRPC who were treated with 
flutamide (375 mg daily) as second-line hormonal therapy. Five androgens 
dehydroepiandrosterone (DHEA), androstenedione, androstenediol, testosterone, and 
dihydrotestosterone (DHT) were measured for investigating the relationship between 
plasma androgens and outcome following treatment. Furthermore we measured the 
adrenal androgen levels in medium of adrenal cancer cell line. 
Results 
Second-line hormonal therapy using flutamide resulted in a reduction of the PSA level 
in 14 (87.5%) of 16 patients. Greater than 50% decline in PSA was observed in 8 (50%) 
of the 16 patients. Median responsiveness duration was 6.25 months. PSA elevation of 
baseline androstenediol level was a predictive factor of PSA responsiveness. The lower 
DHEA group improved duration of responsiveness to flutamide. In vitro, 3 µM 





flutamide suppressed DHEA, androstenedione, and androstenediol synthesis compared 
with bicalutamide in medium of adrenal cancer cell line. 
Conclusions 
Our data demonstrated that flutamide suppressed the adrenal androgens compared with 
bicalutamide. We could predict the responsiveness and response duration of flutamide in 
patients with higher baseline androstenediol level and lower DHEA level. These data 
suggest that metabolites from adrenal androgens contribute to the progression of 
prostate cancer and that flutamide inhibits androgen synthesis. 
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In 2009, prostate cancer was the most commonly diagnosed malignancy in the 
USA.1 Androgen-deprivation therapy is the standard treatment for men with advanced 
prostate cancer. Akaza et al. reported that treatment with bicalutamide (80 mg) in 
combination with an LHRH agonist is superior to LH-RH agonist monotherapy in terms 
of antitumor response at 12 weeks2 In Japan, this combined androgen blockade (CAB) 
has become the most widely used form of hormonal therapy for advanced prostate 
cancer. While almost all patients with prostate cancer show a response to first-line 
hormonal therapy, up to one third of patients eventually experience biochemical 
recurrence. The median duration of responsiveness to CAB has been reported to be 
approximately 16 to 18 months.3 Relapse or progression after hormonal therapy is 
initially detected by an increasing PSA level, which typically predicts the worsening of 
clinical disease by 3 to 12 months.4 Although many urologists provide strategies such as 
radiation therapy or chemotherapy as the next stage of treatment for the progressive 
disease, these therapies have the adverse effects and do not show satisfactory efficacy. 
In 1997, Scher et al. reported that 38.5% of patients with advanced prostate 
cancer who relapsed after first-line hormonal therapy responded to second-line 
hormonal therapy with flutamide.5 In Japan, it has recently been reported that patients 





with castration-resistant prostate cancer (CRPC) responded to second-line hormonal 
therapy using flutamide.6–9 Previous reports showed a PSA decrease exceeding 50% in 
about half of all patients and prolonged clinical benefit with few adverse effects. 
Whitaker reported that not all antiandrogens work via the same mechanism and 
suggested that an informed sequential treatment regime may benefit prostate cancer 
patients.10 It remains unclear why flutamide is effective after first-line hormonal therapy 
using bicalutamide although both antiandrogens are nonsteroidal and bind the same 
ligand-binding domain. Flutamid  may circumvent the mechanisms of failure after 
bicalutamide treatment or act through different means. 
Although CAB using bicalutamide reduces serum testosterone levels by >95%, 
CAB does not reduce adrenal androgens, such as androstenedione, androstenediol, and 
dehydroepiandrosterone (DHEA).11, 12 The persistence of adrenal androgens has clinical 
significance, as these androgens have been shown to activate androgen receptors in 
vitro.13-15 Although several studies have demonstrated the efficacy of flutamide as 
second-line hormonal therapy after using bicalutamide, little is known about the precise 
mechanisms of the effects of this agent. Ayub reported that flutamide is different from 
bicalutamide in decreasing adrenal androgen by suppressing CYP17.16  
It is, therefore, of interest to determine how flutamide affects adrenal 





androgens and whether the levels of adrenal androgens may be of value for predicting 
prognosis in patients with CRPC. We evaluated the PSA responsiveness rate and 
androgen levels in patients with flutamide as second-line hormonal therapy. 
Furthermore we examined the effect of antiandrogens on adrenal androgens secretion in 
adrenal cancer cell line (NCI-H295R). 
 
 
Patients and Methods 
Patients 
The eligibility criterion was histologically confirmed adenocarcinoma of the 
prostate with progressive disease. All patients were initially treated with CAB 
consisting of either surgical or medical castration using LHRH agonist plus 
antiandrogen (80 mg bicalutamide daily) as first-line hormonal therapy. Progression was 
defined as a PSA of > 0.2ng/mL, which had increased from baseline on at least three 
successive occasions at least 4 weeks apart. Patients were excluded if they had received 
prior radical prostatectomy, chemotherapy, immunotherapy, experimental therapy, or 
radiation therapy. All participants gave their inform consent to participation in this study 
in accordance with our institutional guidelines. 






When first-line hormonal therapy was judged to have failed, bicalutamide was 
discontinued to exclude antiandrogen withdrawal (AW). After confirmation of 
increasing serum PSA, subsequent second-line hormonal therapy using 375 mg of 
flutamide daily combined with either surgical or medical castration was started. In this 
series, clinical progression was not considered, and treatment failure was defined as 
increased serum PSA level on three successive occasions, and the response duration was 
regarded as the time from the start of second-line hormonal therapy to failure. 
Good responders were patients in whom the PSA level decreased by more 
than 50% with second-line hormonal therapy, while nonresponders were those in whom 
PSA level continued to rise after commencement of second-line hormonal therapy, and 
others were defined as moderate responders. Patient plasma samples were isolated at 0, 
4, and 12 weeks after commencement of therapy, and frozen until analysis at a 
commercial laboratory to determine androstenedione, androstenediol, DHEA, 
testosterone, and DHT levels by liquid chromatography tandem mass spectrometry 
(LC-MS/MS) at a commercial company (Teikoku Hormone MFG. Co., Kanagawa 
Japan). We divided the patients in two groups according to the median hormonal level 
and compared the PSA progression-free survival between the two groups. 






Statistical analyses were performed using commercial software (Prism; 
Graphpad Software). Statistic analyses of differences in responsiveness to therapy were 
evaluated by the X2 test or log rank test or two-ANOVA with P < 0.05 considered to 
indicate significance in all tests. 
 
The effect of flutamide and bicalutamide on adrenal androgens secretion in vitro 
The NCI-H295 (CRL-2128, ATCC, Rockville, MD, USA) cell line derived from a 
human adrenocortical carcinoma that expressed a multitude eroidogof stenic 
cytochrome P450s and a standard model for the study of human adrenocortical 
steroidogenesis was purchased from American Type Culture Collection (ATCC, 
Manassas VA USA). NCI-H295R cells were maintained in Dulbecco’s modified 
Eagle’s medium/F12 (DMEM/F12, Invitrogen, Renfrew, UK) containing 2% Ultroser 
SF (Biosepra, France), 5 g/ml insulin, 5 g/ml transferrin and 5 ng/ml sodium selenite (as 
1% ITS, Invitrogen). To see the effect of antinandrogens, the cells (3×105 cells per well) 
were treated in the above medium with the appropriate addition of flutamide or 
bicaltamide (0, 0.3, 1, and 3 µM) for 48h. After treatment, we collected the cultivated 
medium and measured adrenal androgens (DHEA, Androstenediol. Androstenedione) in 





it using LC-MS/MS. 
. 
Results 
Sixteen patients (median age, 76 years; range, 65 to 88 years) were recruited 
into this study between 26 May 2005 and 17 December 2008. All patients were 
refractory to first-line hormonal therapy (LH-RH agonist and bicalutamide). The 
median baseline of serum PSA was 122 ng/mL (range, 0.243 to 5904 ng/mL). The 
median nadir PSA after first-line CAB using bicalutamide was 0.700 ng/mL (range, 
0.013 to 13.9 ng/mL). The median time to progression of the first-line hormonal therapy 
was 15 months (range, 3 to 90 months). Antiandrogen withdrawal (AW) was observed 
in three men (18.8%) and the median period of this phenomenon was 4.5 months (range, 
1 to 9.5 months) (Table 1). 
Second-line hormonal therapy using flutamide resulted in a reduction of the 
PSA level in 14 of the 15 patients (87.5%) (Fig. 1). Greater than 50% declines in PSA 
from the start of treatment were observed in 8 (50%) of 16 patients with CRPC. Twelve 
(75%) of 16, 4 (25%) of 16, and 2 (12.5%) of 16 patients had > 30%, > 75%, and > 90% 
declines in PSA 12 weeks after flutamide treatment, respectively. The median nadir PSA 
during second-line CAB was 1.063 ng/mL (range, 0.008 to 1805 ng/mL) and the median 





duration of PSA responsiveness was 6.25 months (range, 1 to 24 months) after the start 
of second-line CAB therapy (Table 2). There were no severe side effects associated with 
second-line hormonal therapy using flutamide.  
We subsequently analyzed several clinical factors associated with PSA 
responsiveness after second-line CAB using flutamide. As shown in Table 3, age, 
pretreatment PSA level, nadir PSA after first-line CAB, time to progression after 
first-line hormonal therapy, and AW PSA levels at the start of second-line hormonal 
therapy were not associated with PSA responsiveness to second-line therapy.  
To investigate the effects of flutamide on adrenal androgens, we examined the 
concentration of serum adrenal androgens of the patients by LC-MS/MS. Since 
LC-MS/MS can examine androgen concentration more accurately than previous assays, 
we used this assay system in the present study. Concentrations of all adrenal androgens 
(DHEA, androstenedione, androstenediol, testosterone, and DHT) decreased from the 
start of second-line CAB (Fig. 2). To investigate the correlation between PSA 
responsiveness and decreases in androgen levels, we classified the patients according to 
the degree of PSA decrease induced by flutamide. Baseline of androstenediol of good 
responders, defined as patients in whom PSA level showed a decrease of ≥ 50% by 
flutamide, was higher than that of patients defined as moderate responders (Fig. 3 A). 





The relationships of all other baseline adrenal androgen levels to 50% PSA decline were 
not significant.  
Furthermore, we demonstrated stratified data on changes in androstenediol level after 
introduction of second-line CAB. (Fig 3 B)  Although androstendiol levels of the good 
respondersthere were higher than that of the moderate responders at base level, there 
were no differences between good responders and moderate responders in decline rate 
of PSA level by flutamide.  
We divided all patients into two groups (high androgen level and lower 
androgen levels) according to the median baseline androgen level to evaluate the 
association between the time to progression and baseline androgens. There were no 
differences in the association between time to progression and androstenediol, 
androstenedione, testosterone, or DHT level (data not shown). When we divided into 
higher and lower DHEA groups according to baseline DHEA level, a significant 
difference in time to progression was observed between the two groups. The median 
DHEA levels in the higher and lower DHEA groups were 1214.2 ng/mL (826.9 to 
1713.7 ng/mL) and 736.2 ng/mL (289.7 to 810.0 ng/mL), respectively. As shown in Fig. 
4, the time to progression of the patients with lower baseline level of DHEA was 
significantly longer than that in those with higher level of DHEA (0 – 24.0 months, 





median 9.75 months vs. 0 – 9.0 months, median 6.00 months, P = 0.04). 
In order to investigate the effect of antiandrogens on adrenal androgen 
synthesis in adrenal gland in vitro,, we examined the concentration of adrenal androgens 
(DHEA, androstenedione, and androstenediol) after treatment with antiandrogens in 
adrenal cancer cell line NCI-H295R. As shown in Fig. 5, 3 µM flutamide (the 
concentration that we can achieve clinically) suppressed all adrenal androgens 
compared with bicalutamide. This result indicated that flutamide inhibited CYP17 
activity more than bicalutamide because the enzyme converted from these three 




The results of the present study indicated that second-line hormonal therapy using 
flutamide decreased adrenal androgens and was effective for bicalutamide-refractory 
prostate cancer. Although several studies have reported the effectiveness of second-line 
hormonal therapy, it was not clear why secondary therapy using flutamide is effective. 
Three hypotheses were proposed regarding the mechanism of the effectiveness of 
second-line hormonal therapy using flutamide: 1) differences in location of androgen 





receptor mutation; 2) differences in affinity for androgen receptors; 3) differences in 
inhibitory effects of androgen synthesis. Hara and Happala reported that the mechanism 
of bicalutamide resistance was mutation of codon 741 in a bicalutamide-resistant cell 
line that they established in vitro.17, 18 On the other hand, Furutani and Kemppainen 
reported that flutamide was superior to bicalutamide in its inhibitory effect on androgen 
receptor transcriptional activity.19, 20 Recent studies also indicated the efficacy of 
ketoconazole and abiraterone, which inhibit cytochrome P (CYP) 17:17α-hydroxylase, 
in suppressing castration-resistant prostate cancer.21, 22 CYP17 is a key enzyme related 
to androgen biosynthesis from cholesterol to DHEA. These reports indicated that 
adrenal androgens still play an important role in prostate cancer progression after 
castration. Ayub et al. reported that flutamide decreased the serum level of testosterone, 
DHT, and DHEA-S by inhibiting the activity of CYP17.16 We focused on the inhibitory 
effects of flutamide on androgen biosynthesis and investigated the prognostic factors in 
second-line hormonal therapy using flutamide. All adrenal androgens were inhibited in 
almost all cases by changing from bicalutamide to flutamide, suggesting that the 
difference in the inhibitory effect of androgen synthesis shows one of the mechanisms 
of the decrease of PSA by flutamide. Furthermore we had been found to suppress the 
adrenal androgen (DHEA, androstenedione and androstenediol) in NCI-H295R by 





flutamide that we can achieve clinically. The results of this study demonstrated that the 
inhibition of adrenal androgens by flutamide was associated with suppression of 
prostate cancer in vitro. 
The purpose of this study was to predict the effect of second-line hormonal 
therapy using flutamide. In terms of the characteristics of the enrolled patients, there 
were no significant differences in the distribution of age, pretreatment PSA, Nadir PSA 
after first line CAB, Time to progression after first-line CAB, antiandrogen withdrawal, 
PSA at start of second-line CAB. Although Kojima found that second-line responders 
tended to have lower PSA levels at the start of second-line CAB,6, we could not prove 
their results in the present study. Miyake and Nishimura also reported that PSA levels at 
the start of second-line CAB had no significant effect on the responsiveness to 
second-line CAB.7, 8 These results demonstrated that patient’s characteristics were not 
associated with the effect of second-line hormonal therapy. 
The present study showed that the patients who experienced a 50% decline in PSA 
in responsiveness to flutamide had a significantly higher baseline level of 
androstenediol compared with those who did not respond. Androstenediol is the 
precursor of testosterone in the adrenal steroid synthesis pathway, and this value may be 
of physiological importance. Furthermore, androstenediol may itself bind to the mutated 





AR, or be converted to DHT, the androgen that binds with the highest avidity to and 
activates AR. Mizokami et al. reported that androstenediol is present in prostate cancer 
tissue after androgen deprivation therapy and activates androgen receptor in 
androgen-sensitive LNCaP cells more effectively than DHEA and androstenedione.12 
Titus et al. and Stanbrough et al. showed that tumors progressing despite androgen 
deprivation therapy may contain measurable concentrations of adrenal androgens as 
well as express the enzymes responsible for conversion of adrenal androgens to 
testosterone.23, 24 A higher androstenediol level may identify patients more likely to 
benefit from flutamide. Although androstenediol was good predictive factor, it was not 
useful for transition of therapy effect because it was a little in serum. We supposed that 
we could use androstenediol levels as predictive factor, but could not use as response 
maker.  
We showed that time to progression of second-line CAB responders with lower DHEA 
levels at the start of second-line CAB was extended relative to that of second-line CAB 
responders with higher DHEA levels. It is possible that the patients with low serum 
DHEA levels have low ability to produce DHEA from the adrenal gland. Because the 
prostate cancer still maintains androgenic sensitivity after the first line CAB, low-level 
androgen should be able to control growth of the prostate cancer. Therefore, since the 
androgenic source after the hormonal therapy is adrenal androgen DHEA, a group of 
the low DHEA level out of the serum will have good PFS. 
 
Montgomery reported that castration-resistant metastases displayed alterations in 





genes encoding steroidogenic enzymes compared with primary prostate tumors, and 
intracrine steroidogenesis may permit tumors to circumvent low levels of circulating 
androgens.25 Stanbrough also demonstrated that the expression of genes associated with 
the conversion of adrenal androgens to testosterone may adapt to androgen 
deprivation.23 However, if there is little supply of DHEA to CRPC, cancer progression 
may be delayed due to the inability to produce sufficient testosterone or DHT.  
Although flutamide is known to act as an androgen receptor antagonist, the 
present study showed that flutamide inhibits biosynthesis of androgens, such as 
testosterone, DHEA, androstenediol, androstenedione, and DHT, and prevents the 
progression of CRPC. We hope to be able to use adrenal androgen as a predictor of the 
efficacy of second-line hormonal therapy. 
 
Conclusions 
Our study indicated that second-line hormonal therapy using flutamide resulted in 
improvement of clinical outcome in 50% of patients who relapsed after CAB using 
bicalutamide. Moreover, these data suggest that the baseline levels of androstenediol 
and DHEA are predictive factors of clinical outcome in patients with castration-resistant 
prostate cancer. We intend to further clarify those patients that are most likely to benefit 





from flutamide and to target the mechanism of eventual resistance to flutamide therapy. 
It will be necessary to collect data from more patients and examine the adrenal androgen 
levels to accurately investigate the prognostic factors after alternative antiandrogen 
therapy. 
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Fig. 1 Changes in PSA with flutamide. The waterfall plot shows the percentage change 
of PSA from baseline 12 weeks after flutamide treatment. The dashed line indicates 
50% PSA decrease from baseline. 
 
Fig. 2 Time course of changes in serum levels of various androgens after flutamide 
treatment. Columns show various serum androgens (DHEA, androstenediol, 
androstenedione, testosterone, and DHT) levels measured by LC-MS/MS analysis at 
baseline and 4 and 12 weeks after flutamide treatment. The data show the means ±SD of 
serum androgen levels in all patients. Concentrations of all adrenal androgens decreased 
from the start of second-line CAB. 
 
Fig. 3 Serum levels of various androgens in the good and intermediate responder groups. 
(A) Serum levels of various androgens in the good and intermediate responder groups. 
after introduction of second-line CAB. (B) A chronologic change of androstenediol after 
the second line CAB using flutamide. The data show the means ± SD of serum 
androgen levels of each group. 






Fig. 4 Time to progression in responders. The patients who responded to flutamide  (n 
= 14) were divided into two groups by baseline DHEA level. The Kaplan-Meier plot 
shows the time to PSA progression on flutamide treatment. The two lines show the 
lower DHEA level group (red line) and higher DHEA level group (blue line). The time 
to progression of the patients with lower baseline level of DHEA was significantly 
longer than that in those with higher level of DHEA. 
 
 
Fig 5 The effect of bicalutamide and flutamide on the adrenal androgen synthesis in 
adrenal cancer cell line. Forty-eight h after treatment with the indicated concentrations 
of bicalutamide or flutamide, the cultivated medium was collected and the concentration 
of DHEA, androstenediol, and androstenedione were measured by LC-MS/MS analysis. 
Columns and bars represent the means ± SD (n=3). * P<0.05.  
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1 80 N/A 17.4 13 1.1 D2 1 2.7 115.1 17.8 675.8 313.4 20.2 No 0
2 67 4+3 101.9 15 0.2 D2 1 1.96 144.2 20.5 1494.2 562.6 71.9 47 6.5
3 77 4+5 7416.5 10 2.8 D2 4 5904 53.4 14.5 1130.9 280.3 67.0 26 1.75
4 69 3+5 40.66 23 0.06 D2 1 0.83 100.0 19.4 720.4 504.4 36.2 34 4.25
5 84 4+5 268.7 3 2.172 D2 1 11.278 130.3 35.2 1297.6 347.6 85.9 36 6
6 81 3+4 91.6 23 0.2 B2 0 0.243 70.1 16.3 752.1 117.0 93.8 71 26
7 71 N/A 29.1 60 0.1 D2 1 2.299 85.6 4.4 765.6 303.7 101.0 82 9.75
8 78 3+5 115.2 28 1.23 B1 0 5.12 55.9 2.7 930.5 234.6 53.7 67 9
9 88 4+5 1215 11 13.854 D2 4 70.557 74.9 12.8 289.7 214.0 32.8 34 3
10 74 5+4 84.4 10 0.961 D2 2 135.967 43.7 12.0 810.0 374.6 113.7 99 7
11 76 4+5 149.5 15 0.6 D2 1 5 77.3 7.0 777.0 206.4 46.8 86 17
12 72 4+5 221.5 66 0.2 C 0 1.589 89.6 22.1 1713.7 259.3 212.9 50 8
13 66 4+5 1813 64 0.1 D2 4 1.04 112.02 38.11 1460.69 509.37 191.51 63 8
14 76 N/A 18 90 0.8 N/A N/A 4.37 71.42 7.00 424.78 253.14 39.68 12 8
15 65 4+5 1600 10 0.932 D2 4 7.58 124.98 8.14 863.78 552.78 78.38 99 6.5
16 75 4+3 122 14 0.013 D1 0 9.68 40.62 11.04 826.90 104.92 128.98 No 0
GS: Gleason score, T: testosterone, Adione: androstenedione, Adiol: androstenediol
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Table2 Treatment outcomes range
Response to first-line CAB
CR 15
PR 1
Median : after first-line CAB
 nadir PSA (ng/mL) 0.7 (0.013-5904)




Median peiod of antiandrogen withdrawal phenomenon (months) 4.5 (1-9.5)




Median : after second-line CAB
PSA at start of second-line hormonal therapy (ng/mL) 4.6835 (0.243-5904)
 nadir PSA (ng/mL) 1.063 (0.387-1805)
time to progression (months) 6.25 (0-24)
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Table 3 Association between factors and respose to second-line CAB therapy
pts response pts (%) p-value
Age (years) 0.310
75 or more 9 3 (33%)
under 75 7 5 (71%)
Pretreatment PSA level (ng/ml) 1.000
150 or more 6 3 (50%)
under 150 10 5 (50%)
Nadir PSA after firstline CAB (ng/ml) 0.282
1 or more 5 1 (20%)
under 1 11 7 (64%)
Time to progression after first-line CAB (months) 0.310
15 or more 9 6 (67%)
under 15 7 2 (28.6%)
Antiandrogen withdrawal 1.000
Yes 3 2 (67%)
No 13 6 (46.2%)
PSA at start of second-line CAB (ng/ml) 1.000
2 or more 11 5 (45.5%)
under 2 5 3 (60%)
CAB:combined androgen blockade





Fig. 1 Changes in PSA with flutamide. The waterfall plot shows the percentage change of PSA from 
baseline 12 weeks after flutamide treatment. The dashed line indicates 50% PSA decrease from 
baseline.  
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Fig. 2 Time course of changes in serum levels of various androgens after flutamide treatment. 
Columns show various serum androgens (DHEA, androstenediol, androstenedione, testosterone, and 
DHT) levels measured by LC-MS/MS analysis at baseline and 4 and 12 weeks after flutamide 
treatment. The data show the means ±SD of serum androgen levels in all patients. Concentrations 
of all adrenal androgens decreased from the start of second-line CAB.  
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Fig. 3 Serum levels of various androgens in the good and intermediate responder groups. (A) Serum 
levels of various androgens in the good and intermediate responder groups. after introduction of 
second-line CAB. (B) A chronologic change of androstenediol after the second line CAB using 
flutamide. The data show the means ± SD of serum androgen levels of each group.  
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Fig. 4 Time to progression in responders. The patients who responded to flutamide  (n = 14) were 
divided into two groups by baseline DHEA level. The Kaplan-Meier plot shows the time to PSA 
progression on flutamide treatment. The two lines show the lower DHEA level group (red line) and 
higher DHEA level group (blue line). The time to progression of the patients with lower baseline 
level of DHEA was significantly longer than that in those with higher level of DHEA.  
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Fig 5 The effect of bicalutamide and flutamide on the adrenal androgen synthesis in adrenal cancer 
cell line. Forty-eight h after treatment with the indicated concentrations of bicalutamide or 
flutamide, the cultivated medium was collected and the concentration of DHEA, androstenediol, and 
androstenedione were measured by LC-MS/MS analysis. Columns and bars represent the means ± 
SD (n=3). * P<0.05.  
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